Vertical software45% entry signalMarket screenOne thing must be trueincumbent vulnerability

LIMS — Laboratory Information Management Systems for Testing, QC and Research Labs

Prepared 2026-10-08

The buyer population — Testing laboratories

Base industry report for 541380 →
Establishments · CanadaA
1,439
with employees
Under 10 employeesA
59%
most common size: 1–4
Establishments · USA
7,488
Employment · USA
154,715
21 per establishment
Payroll · USA
$11.4B
$74k per employee

Of 1,439 Canadian establishments with employees, 59% have fewer than ten — mostly small operators. Each of those is one potential account, before any filter for size or fit.

Entry signal — what decides who wins here

One thing must be true
Structure decides One thing must be true Execution decides

Entry turns on a single condition that can be named and tested before much is spent. Clear it and this becomes an execution question; fail it and no amount of operating skill helps.

What you would have to beat

Displace an incumbent the screen found well defended — payments attached to the workflow, data that does not leave, a contract that renews itself. Share here means giving a buyer a reason to break something that currently works, which is a higher bar than being better.

How it was read
Binding constraintUNVERIFIEDincumbent vulnerability — Executional — a better operator can move it.
Measured inputsUNVERIFIEDnot applied — This is a software market. The industry’s business counts describe its BUYERS, not the market being entered, so they are left out of the signal.
How many new establishments are still tradingA
Professional, Scientific, and Technical Services, US · opened 2020
83.3%
1 year
64%
3 years
50.8%
5 years
34.3%
10 years
opened 2015

Measured, not forecast: the share of US establishments opening in one year that were still active later. It counts good operators and bad ones together, which is exactly why it is the honest answer to “what are the odds”. It is for the whole sector rather than this market, and the ten-year figure comes from an older cohort because no younger one has reached ten years.

This is not a probability of success, and it is not a verdict on you. No survival probability is published per market, and inventing one would be worse than saying so. What the bar reads is how much of the outcome sits inside an operator's control: green means the hurdles are ones a better operator clears, red means the binding constraint is capital, an asset or a permission rather than execution. Someone arriving with an advantage this screen did not assume can win a market shown in red.

Companies named in this market · 16

The binding constraint — incumbent vulnerability

Two private LIMS houses that have each sold into labs for about forty years hold the top of this market, and validation keeps their customers in place. LabWare (Wilmington, Delaware; founded 1987 and still run by its founder) claims 30,000 laboratories at 2,500 companies in 125 countries, with all R&D in Wilmington [C]. StarLIMS (Hollywood, Florida; founded 1986) belonged to Abbott from 2010 to 2021. Francisco Partners bought it from Abbott in July 2021, terms not disclosed [B, FP release]. On 13 January 2026 Turn/River Capital bought it outright and Francisco Partners exited [B, release], so it has had three owners in five years. StarLIMS claims 1,100+ customers in 2,000+ labs [C]. LabVantage (Somerset, NJ) is the third independent. It is private, has never disclosed an owner, and grew by buying Life Technologies' SQLLIMS in 2009 [B]. The instrument makers sell LIMS too, and they bundle it with their hardware: Thermo Fisher (SampleManager for QC and manufacturing, Watson for bioanalysis, Core LIMS for R&D), Agilent (SLIMS, from its 2018 Genohm deal), Waters (NuGenesis) and Illumina (Clarity LIMS, for genomics labs; it is not* a Revvity product). None of them reports a LIMS revenue line. The R&D notebook side is where the money went: Benchling raised $100M at a $6.1B valuation in 2021 [B, release], and Siemens bought Dotmatics for $5.1B in July 2025, a company expected to earn more than $300M in FY2025 [B, Siemens release]. Siemens does have a lab play, then, but it came through Dotmatics, not Opcenter. At the bottom, CloudLIMS publishes per-user prices: $285 a user a month at 5 users, falling to $42 at 100 users, billed annually [C, pricing page]. LabLynx, CloudLIMS and Kitchener's Scispot (about $10M raised) already serve small labs. The lock-in is the validation, not the software. A pharma QC or GLP lab that switches LIMS has to revalidate the new system under 21 CFR Part 11 or GxP, and an ISO 17025 lab has to show its accreditation body that results stay traceable through the move. Instrument interfaces, specifications and years of audit trail have to be migrated too. Customers stay for decades, which is why both leaders can be thirty-plus years old. How it differs from its neighbours. The clinical-trial and R&D data record covers EDC, CTMS and the R&D cloud, where Benchling and Dotmatics live. This record is the system of record for the sample and the result in testing and QC labs. The food-safety record covers plant-floor safety and FSMA 204 traceability, not the lab that tests the samples. Imaging/PACS is radiology. Clinical lab systems are a separate, hospital-bought market. Epic's Beaker module, Clinisys (Roper Technologies) and Orchard Software, which Clinisys bought from Francisco Partners in July 2025 [B], are listed here only to mark that boundary. Incumbent vulnerability decides it: the two leaders are stable, the instrument makers bundle LIMS with their hardware, and the low end already has vendors that publish their prices.

I

The incumbent

Who owns this market and who is coming for it. Fields a screen never reached say so rather than guessing.

Incumbent
LabWare (founder-owned, Wilmington, 1987), with StarLIMS (Turn/River Capital since January 2026) as the other long-standing independent; the instrument makers (Thermo Fisher SampleManager, Agilent SLIMS, Waters NuGenesis) bundle LIMS with their instruments
Scale
No LIMS vendor publishes revenue. LabWare claims 30,000 labs in 125 countries [C]; StarLIMS claims 1,100+ customers in 2,000+ labs [C]. The only figure from an adjacent vendor: Dotmatics, mostly R&D software, expected to exceed $300M revenue in FY2025 when Siemens bought it for $5.1B [B]
Challengers
LabVantage, Thermo Fisher (SampleManager, Watson), Agilent SLIMS, Clinisys (Roper), Benchling and Dotmatics (Siemens) from the R&D/ELN side; CloudLIMS, LabLynx and Scispot at the small-lab end
Lock-in mechanism
Very high in regulated labs. Switching means revalidating the new system (21 CFR Part 11, GxP computerised-system validation), re-showing ISO 17025 traceability to the accreditation body, rebuilding instrument interfaces and specifications, and migrating years of audit trail. Lower for small unregulated labs, where a SaaS LIMS can be set up in weeks
Price movement
The bottom is public: CloudLIMS lists $285 a user a month at 5 users, falling to $42 at 100 users, billed annually [C]. Enterprise LIMS is quoted privately with implementation and validation services; no enterprise price was found
Is the buyer consolidating?
Yes — The vendors are consolidating more than the buyers. Ownership has changed at StarLIMS (Abbott → Francisco Partners → Turn/River, 2021–2026), Orchard (Francisco Partners → Clinisys/Roper, 2025), Dotmatics (Insight → Siemens, 2025) and Genohm (→ Agilent, 2018). Among the buyers, contract testing networks keep buying independent labs, though that was not measured here
$

Market size, derived

Built from the competitor set upward rather than quoted from a forecast. Published TAMs in these categories are frequently reverse-engineered from each other, so any published figure is checked against the vendor arithmetic rather than trusted on its own.

Revenue floor
$300M

Disclosed revenue from 1 of 13 named vendors. The market is at least this large.

Implied total — revenue ÷ share
—

No vendor has both a disclosed revenue and a published share.

Published forecast
—Floor only

Only a revenue floor is known — the true market is larger by whatever the undisclosed vendors earn.

Competitor set · 13 named · 1 disclose revenue

NameRevenueShareNote
LabWareC not disclosed — Private, founder-led since 1987; no revenue or funding disclosed — Wilmington, DE; LIMS + ELN; claims 30,000 labs, 2,500 companies, 125 countries, 150,000 daily users [C]
StarLIMSB not disclosed — Private. Abbott owned it 2010–2021; Francisco Partners bought it July 2021 (terms undisclosed); Turn/River Capital bought it 2026-01-13 and FP exited (price undisclosed; a ~$200M figure seen only on a deal aggregator is not used) — Hollywood, FL; founded 1986; claims 1,100+ customers in 2,000+ labs; added the Labstep ELN [C]
LabVantageB not disclosed — Private; owner not disclosed in anything opened. Bought Life Technologies' SQL*LIMS business (completed 10 Aug 2009) [B] — Somerset, NJ. labvantage.com refused automated retrieval (403), so no claims from its own site are used here
Thermo FisherC not disclosed — LIMS not broken out by Thermo Fisher Scientific (NYSE: TMO) — SampleManager (QC/manufacturing), Watson (bioanalysis), Core LIMS (R&D), all on its own LIMS page [C]
Agilent (SLIMS)B not disclosed — Not broken out. Agilent (NYSE: A) announced the Genohm (Lausanne) acquisition in May 2018, terms undisclosed [B, Scientific Computing World] — SLIMS combines LIMS and ELN for biobanks, research and NGS labs; agilent.com refused automated retrieval (403)
Waters (NuGenesis)C not disclosed — Not broken out; Waters' page timed out and was not opened — NuGenesis lab management system, sold into chromatography-heavy QC labs
Illumina (Clarity LIMS)C not disclosed — Not broken out by Illumina — Clarity LIMS is an Illumina product for genomics labs (on illumina.com), not a Revvity one
BenchlingB not disclosed — Private. $100M Series F at a $6.1B valuation, 2021-11-18, co-led by Franklin Templeton and Altimeter, with Tiger Global and Lone Pine [B, company release]; no total disclosed by the company — San Francisco; R&D cloud (ELN, registry, workflows) for biotech. It sits mostly in the neighbouring R&D-data record
Dotmatics (Siemens)B $300M — Siemens expected Dotmatics to exceed $300M of revenue in FY2025 with an adjusted EBITDA margin above 40%; acquisition closed July 2025 at a $5.1B enterprise value, seller Insight Partners [B, Siemens release] — Boston; Luma platform, Geneious and an ELN; now part of Siemens Digital Industries Software
Revvity SignalsC not disclosed — Not broken out by Revvity; revvitysignals.com refused automated retrieval (403) — Signals Notebook ELN. It does not own Clarity LIMS (that is Illumina)
ClinisysB not disclosed — Roper Technologies business, not broken out. Bought Orchard Software from Francisco Partners, announced 2025-07-29, terms undisclosed [B, release] — Clinical LIS plus LIMS for environmental, water, food, public-health and contract labs; claims 7,000+ labs in 42 countries [C]
Orchard SoftwareB not disclosed — Acquired by Clinisys (Roper) in July 2025; Francisco Partners owned it from 2019 — A clinical lab system (LIS), not a testing-lab LIMS. Founded 1993; claims 2,000+ US labs in physician groups, hospitals, reference and veterinary labs [C]
Epic SystemsC not disclosed — Private; no lab figure — Beaker is Epic's laboratory module inside its EHR, a clinical lab system bought with the hospital record (listed under Specialties on epic.com)
S

Startups & challengers

Newer and smaller vendors going at the incumbent — funded challengers first. Named, not researched to the depth of the field above; a company with a page here links to it.

CompanyStageWhat it doesRaised
Scispot Funded challenger Kitchener, Ontario; AI-native lab OS (ELN + LIMS) for biotech, diagnostics and testing labs; $8M Series A, Avenue Growth Partners lead, 2026 $10m
CloudLIMS Scrappy competitor SaaS LIMS for testing labs, biobanks and clinical labs; publishes per-user pricing from $285 (5 users) down to $42 (100 users) —
LabLynx Scrappy competitor Atlanta; LIMS, ELN and lab automation suites for analytical, food & beverage and environmental labs —

Evidence

Evidence. Opened 2026-10-18. Tier B (releases and trade coverage opened): Francisco Partners on the July 2021 deal (signed a definitive agreement to buy STARLIMS from Abbott, terms not disclosed). The StarLIMS / Turn/River release of 2026-01-13 on franciscopartners.com (Turn/River investment, FP exits, 1,100+ customers and 2,000+ labs). The Clinisys release of 2025-07-29 (Orchard bought from Francisco Partners, Roper Technologies named, Orchard founded 1993). The Siemens closing release (Dotmatics, $5.1B EV, Insight Partners seller, revenue expected above $300M in FY2025). Benchling's release of 2021-11-18 ($100M Series F at $6.1B). Scientific Computing World on Agilent–Genohm (2018) and on LabVantage–SQLLIMS (2009). The Velocity incubator news item on Scispot's $8M Series A (total nearly $10M). Tier C:* vendor claims on their own pages (LabWare's 30,000 labs; StarLIMS's founding year 1986; Clinisys's 7,000 labs; CloudLIMS's published per-user prices); product listings on the Thermo Fisher, Illumina and Epic sites. Not sourced: no vendor publishes LIMS revenue, apart from Siemens' FY2025 expectation for Dotmatics, which is mostly an R&D-software business. No market-size figure was opened, so market size and LIMS vendor revenue are UNVERIFIED. labvantage.com, revvitysignals.com, agilent.com and businesswire.com refused automated retrieval (403), and waters.com timed out, so those vendors' own claims are not used. A ~$200M price for the Turn/River deal appears only on a deal aggregator and is not used. Owners of privately held LabVantage are not named. The 541380 anchor is the customer industry (testing labs). Clinical labs (621510) appear only as a boundary.

#

Where the industry talks

The associations, forums and events where people in this trade actually talk shop — where to listen before entering, and where the first customers are found. Each link was opened on the date shown.

AssociationCanadaA
CALA — Canadian Association for Laboratory Accreditation
cala.ca

Accredits Canadian testing labs (ISO/IEC 17025) and runs a public search for CALA-accredited labs; its CALA Connects 2027 conference is in Calgary on May 19, 2027.

Checked 2026-10-18
AssociationInternationalA
SLAS — Society for Laboratory Automation and Screening
slas.org

Professional society for lab automation and informatics; publishes SLAS Discovery and SLAS Technology and runs a Sample Management Symposium.

Checked 2026-10-18
EventInternationalA
SLAS2027 International Conference & Exhibition
slas.org

January 30 – February 3, 2027, San Diego, CA; the main automation and lab-informatics trade show.

Checked 2026-10-18
ForumInternationalA
LIMSforum
limsforum.com

Laboratory-informatics professional community with a newsletter, articles and vendor webinars (October 2026 listings); sponsor-funded.

Checked 2026-10-18
PublicationInternationalA
LIMSwiki
limswiki.org

Laboratory, health and science informatics encyclopedia with 3,165 articles, including vendor pages.

Checked 2026-10-18

ACIL (acil.org) and Lab Manager (labmanager.com) sit behind Cloudflare challenges or 403s, and Pittcon and ASTM refused automated retrieval, so none of them is listed. The CALA Connects conference sits on CALA's homepage, so it has no separate entry.

↔

The businesses it sells to

Operating-business records filed along the same branch of NAICS — the customers of this software, screened as businesses in their own right.

No operating-business record has been written along this branch yet. The base industry report says what the subsector typically runs on.

Other software on this branch